3.40
+0.215(+6.75%)
Currency In USD
| Previous Close | 3.19 |
| Open | 3.15 |
| Day High | 3.4 |
| Day Low | 3.15 |
| 52-Week High | 13.56 |
| 52-Week Low | 1.6 |
| Volume | 741,718 |
| Average Volume | 812,560 |
| Market Cap | 252.47M |
| PE | -2.48 |
| EPS | -1.37 |
| Moving Average 50 Days | 3.62 |
| Moving Average 200 Days | 3.11 |
| Change | 0.22 |
If you invested $1000 in Perspective Therapeutics, Inc. (CATX) 10 years ago, it would be worth $248.18 as of September 29, 2025 at a share price of $3.4. Whereas If you bought $1000 worth of Perspective Therapeutics, Inc. (CATX) shares 5 years ago, it would be worth $586.21 as of September 29, 2025 at a share price of $3.4.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Perspective Therapeutics Progresses Dose Finding for [212Pb]VMT01 in Combination with Nivolumab in its Ongoing Phase 1/2a Study of MC1R-Positive Metastatic Melanoma
GlobeNewswire Inc.
Sep 15, 2025 11:00 AM GMT
First patient dosed with [212Pb]VMT01 3.0 mCi in combination with nivolumab[212Pb]VMT01 3.0 mCi single agent dose Cohort re-opened SEATTLE, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AM
Perspective Therapeutics Appoints Biotech Veteran Joel Sendek as Chief Financial Officer
GlobeNewswire Inc.
Sep 04, 2025 11:00 AM GMT
Distinguished career as a Wall Street analyst and significant CFO experience, bringing keen insights and understanding of finance and the life sciences investment landscapeSEATTLE, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc.
Perspective Therapeutics Appoints Maya Martinez-Davis to Board of Directors
GlobeNewswire Inc.
Sep 03, 2025 11:00 AM GMT
SEATTLE, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that i